Penumbra, Inc. (BMV:PEN)
| Market Cap | 224.08B +5.2% |
| Revenue (ttm) | 25.27B +17.5% |
| Net Income | 3.20B +1,168.1% |
| EPS | 81.37 +1,155.6% |
| Shares Out | n/a |
| PE Ratio | 70.05 |
| Forward PE | 64.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Average Volume | 446 |
| Open | 4,775.70 |
| Previous Close | 4,911.82 |
| Day's Range | 4,775.70 - 4,775.70 |
| 52-Week Range | 3,904.75 - 4,911.82 |
| Beta | n/a |
| RSI | 55.88 |
| Earnings Date | Apr 30, 2026 |
About Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ... [Read more]
Financial Performance
In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.
Financial numbers in USD Financial StatementsNews
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decembe...
Boston Scientific announces results for fourth quarter and full year 2025
MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported b...
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach
Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions i...
Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.
The cash-and-stock acquisition values Penumbra at $374 a share.
Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments
Penumbra's stock was up about 14% after the deal was announced Thursday morning.
Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock
Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Boston Scientific to buy Penumbra in deal valued at $14.5 billion
Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth ...
Boston Scientific announces agreement to acquire Penumbra, Inc.
Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, ...
Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P.
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on We...
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden ...
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thro...
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
ALAMEDA, Calif. , Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM ...
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif. , Sept. 9, 2025 /PRNewswire/ -- The American Ve...
Penumbra, Inc. Names Shruthi Narayan as Company President
ALAMEDA, Calif. , Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effe...
Penumbra, Inc. to Present at Upcoming Investor Conferences
ALAMEDA, Calif. , Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times...
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tu...
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
ALAMEDA, Calif. , July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market clos...
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatm...
